Red Pharmacy

HOLLISTON, Mass., Nov. 29, 2011 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq:HBIO), a tellurian developer, manufacturer, and marketer of a extended operation of collection to allege life scholarship investigate and regenerative medicine, announces that a “InBreath” bioreactor was used for a world’s second successful transplantation of a fake tissue-engineered windpipe during a Karolinska University Hospital in Stockholm, Sweden. The patient, Mr. Christopher Lyles, is creation a good recovery. This transplant follows a world’s initial fake trachea transplant in Jun 2011, for Mr. Andemariam Beyene, that was reported in a peer- reviewed essay in The Lancet on Nov 24, 2011 during http://www.thelancet.com/. The tracheas in both procedures were grown in Harvard Bioscience’s bioreactors that were constructed in a regenerative medicine device business.

Mr. Lyles, a 30-year aged U.S. citizen, had been pang from late-stage tracheal cancer that would have been inoperable before this transplantation medicine became possible. He is recuperating well, is not holding immunosuppressive drugs and is approaching to be liberated from a sanatorium within a month. To perspective a news shred on Mr. Lyles before to his outing to Sweden and learn about his story, visit: http://www.wbaltv.com/r/29778764/detail.html . To see cinema of a procession that was used for Mr. Lyles’ transplant, visit: http://www.digitalbucket.net/browse/d399e20e41851bf7/Lyles%2520Transplant%2520Static%2520Images and to perspective a brief video of a procession visit: http://vimeo.com/32527358 . The cue in both cases is stockholm11. Mr. Lyles swell can be followed at: www.facebook.com/regeneratelife.

The operation was achieved on Nov 17, 2011 during Karolinska University Hospital in Stockholm, by Professor Paolo Macchiarini of Karolinska University Hospital and Karolinska Institutet, and colleagues. Professor Macchiarini led an general group including Nanofiber Solutions of Columbus, Ohio, who designed and built a nanofiber tracheal scaffold, and Harvard Bioscience, who constructed a privately designed bioreactor used to seed a skeleton with a patient’s possess branch cells. The cells were grown on a skeleton inside a bioreactor for dual days before transplantation into a patient. Because a cells used to renovate a trachea were a patient’s own, there has been no rejecting of a transplant, and a studious is not holding immunosuppressive drugs.

David Green, President of Harvard Bioscience, commented: “We would like to honour Dr. Macchiarini and his group for successfully completing a world’s second fake trachea transplant. This proves that a procession is not a ‘one off’ yet can be repeated. This is a poignant feat for regenerative medicine, and we are respected to attend with a use of a ‘InBreath’ bioreactor. It is critical to note that nonetheless this is a second successful trachea transplant, it is a initial procession on a U.S. studious and with a U.S.-made scaffold. This was done probable interjection to a partnership with Nanofiber Solutions. With a success of these procedures, it is rewarding to see scholarship novella incited into medical reality, and we demeanour brazen to serve swell in regenerative medicine.” 

Ross Kayuha, CEO of Nanofiber Solutions, commented: “We wish to honour Dr. Macchiarini and his surgical team. It is an respect to minister to this life-saving procedure, and we wish Mr. Lyles good health and a prolonged life. Successfully implanting a fake trachea regulating a patient’s possess branch cells is a poignant miracle for regenerative medicine, and we demeanour brazen to participating in a space by a partnership with Harvard Bioscience.”

Harvard Bioscience Regenerative Medicine Strategy:   

Harvard Bioscience’s plan in regenerative medicine is: to emanate devices, not learn pharmaceuticals, as this reduces risk compared to a therapeutics company; to build these inclination regulating a existent technologies and brands, as this reduces a investment indispensable to get to market; and to rise inclination with a poignant disposable income stream, as this is both clinically fascinating and allows Harvard Bioscience to attend on a per-procedure basement and not usually on a sale of an instrument. The association estimates that a nascent marketplace for regenerative medicine inclination could potentially grow to hundreds of millions of dollars annually. 

Harvard Bioscience’s regenerative medicine collection can be found at: http://www.harvardbioscience.com/regenMed.cfm

Note that both Harvard Bioscience’s and Nanofiber Solutions’ regenerative medicine products are now for investigate use only, and are not for use in humans unless correct internal investigational device regulations have been followed.

About Harvard Bioscience

Harrvard Bioscience (“HBIO”) is a tellurian developer, manufacturer and marketer of a extended operation of specialized products, essentially apparatus and systematic instruments, used to allege life scholarship investigate and regenerative medicine. We sell a products to thousands of researchers in over 100 countries essentially by a 850 page catalog (and several other specialty catalogs), a website, by distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and around a margin sales organization. HBIO has sales and production operations in a United States, a United Kingdom, Sweden, Germany and Spain with additional comforts in France and Canada. For some-more information, greatfully revisit www.harvardbioscience.com.

The Harvard Bioscience, Inc. trademark is accessible during http://www.globenewswire.com/newsroom/prs/?pkgid=6426

Forward-looking Statements

The statements done in this press recover that are not statements of chronological fact are forward-looking statements within a definition of Section 27A of a Securities Act of 1933 and Section 21E of a Securities Exchange Act of 1934. You can brand these forward-looking statements by a use of such difference as “will,” “guidance,” “objectives,” “optimistic,” “potential,” “future,”  “expect,” “plans,” “estimates,” “continue,” “drive,” “strategy,” “crucial,” “potential,” “potentially,” “growth,” “long-term,” “projects,” “projected,” “produce,” “intends,” “believes,” “goals,” “sees,” “seek,” “develop,” “possible,” “new,” “enabling,” “emerging,” “opportunity,” “pursue” and identical expressions that do not describe to chronological matters. Forward-looking statements in this press recover might include, yet are not singular to, statements or inferences about a HBIO’s or management’s beliefs or expectations, a margin of regenerative medicine, opportunities or intensity opportunities in a margin of regenerative medicine, HBIO’s business strategy, a positioning of HBIO for growth, a marketplace direct and event for HBIO’s stream products or products it is building or intends to develop, and HBIO’s plans, objectives and intentions that are not chronological facts.

These statements engage famous and opposite risks, uncertainties and other factors that might means HBIO’s tangible results, opening or achievements to be materially opposite from any destiny results, opening or achievements voiced or pragmatic by a forward-looking statements. Factors that might means HBIO’s tangible results, opening or achievements to differ materially from those in a forward-looking statements include, yet are not singular to, HBIO’s disaster to successfully enhance a product offerings, deliver new products or commercialize new technologies, including in a margin of regenerative medicine, decreased direct for a HBIO’s products, including products in a margin of regenerative medicine, due to changes in a customers’ needs, a ability to obtain regulatory approvals, including FDA approval, for a products, including any products in a margin of regenerative medicine, a stream distance or expected distance of a regenerative medicine market, a existence and distance of opportunities in a regenerative medicine market, a financial position, and risk factors set onward underneath a streamer “Item 1A. Risk Factors” in HBIO’s Annual Report on Form 10-K for a mercantile year finished Dec 31, 2010 or described in HBIO’s other open filings. HBIO’s formula might also be influenced by factors of that HBIO is not now aware. HBIO might not refurbish these forward-looking statements, even yet a conditions might change in a future, unless it has obligations underneath a sovereign bonds laws to refurbish and divulge element developments associated to formerly disclosed information.

CONTACT: Harvard Bioscience, Inc.
         David Green, President
         dgreen@harvardbioscience.com
         Chane Graziano, CEO
         cgraziano@harvardbioscience.com
         Tom McNaughton, CFO
         tmcnaughton@harvardbioscience.com
         508 893 8999
         Fax: 508 429 8478